Yousef Zakharia

2 months ago | onclive.com | Yousef Zakharia

CommentaryVideoJanuary 28, 2025Author(s):Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma. “With longer follow-up, we are seeing more of a flip of the OS curve in favor of ipilimumab plus nivolumab in the favorable-risk patient population.

Jul 5, 2024 | urotoday.com | Yousef Zakharia

Read the Full Video TranscriptPedro Barata: Hello. I'm Dr. Pedro Barata, GU oncologist at University Hospital Seidman Cancer Center in Cleveland. I'm very, very happy to be joined by Dr. Yousef Zakharia, a colleague and friend and kidney cancer expert. He's a full professor of medicine at Iowa University. He's also the director of the phase one and the co-leader of the gene malignancy there at the Holden Comprehensive Cancer Center. Such a pleasure to have you here, Yousef. Yousef Zakharia: Hi, Pedro.

Feb 27, 2024 | nature.com | Nicholas A. Zorko |Yousef Zakharia |Vivek Narayan |Elisabeth I. Heath |Allison Makovec

AbstractNatural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline.

Nov 10, 2023 | onclive.com | Yousef Zakharia

November 10, 2023Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.